Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
IN8bio ( (INAB) ) has shared an update.
On February 26, 2026, IN8bio, Inc. announced that director Alan S. Roemer had notified the Board of his decision to resign from the Board and from the Audit and Compensation Committees, effective February 28, 2026. The company stated that his resignation did not arise from any disagreement over operations, policies or practices, and the Board appointed independent director Jeremy Graff as Interim Chair effective the same date, signaling a planned and orderly leadership transition in its governance structure.
The most recent analyst rating on (INAB) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on IN8bio stock, see the INAB Stock Forecast page.
Spark’s Take on INAB Stock
According to Spark, TipRanks’ AI Analyst, INAB is a Neutral.
The score is held back primarily by weak financial fundamentals typical of a pre-revenue biotech (ongoing losses/cash burn and equity erosion). Offsetting factors include constructive near-term technical momentum and supportive corporate catalysts (positive trial/preclinical updates and a structured financing that improves liquidity runway).
To see Spark’s full report on INAB stock, click here.
More about IN8bio
IN8bio, Inc. operates in the biotechnology sector and is led by a Board of Directors that oversees its strategic direction and corporate governance. The company’s board structure includes independent directors and specialized committees such as Audit and Compensation, reflecting a focus on regulatory compliance and oversight within its industry.
Average Trading Volume: 281,296
Technical Sentiment Signal: Sell
Current Market Cap: $15.14M
For an in-depth examination of INAB stock, go to TipRanks’ Overview page.